Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update

Bioxytran, Inc. (OTCMKTS:BIXT) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 3,506 shares, a decline of 98.4% from the March 31st total of 220,491 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 460,206 shares, the days-to-cover ratio is presently 0.0 days.

Bioxytran Stock Down 3.0%

BIXT stock traded down $0.00 during trading hours on Friday, hitting $0.04. The company’s stock had a trading volume of 45,000 shares, compared to its average volume of 186,307. The stock has a 50 day moving average price of $0.04 and a two-hundred day moving average price of $0.06. Bioxytran has a 12 month low of $0.03 and a 12 month high of $0.17. The company has a market capitalization of $3.97 million, a PE ratio of -1.75 and a beta of 2.50.

Bioxytran Company Profile

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.